New Quinoline-Based Proteasome Inhibitors
- Detailed Technology Description
- Executive Summary There are several existing cancer treatments that are effective at inducing cell death by decreasing proteasome activity: Velcade® (bortezomib) and Kyprolis® (carfilzomib). Due to undesirable side effects and pharmacodynamics properties, these agents have been limited to treating blood cancers. MSU researchers have developed a new class of therapeutic compounds with a unique mode of action and more promising pharmacodynamics. Description of Technology This technology uses a new class of quinoline-based proteasome inhibitors. These compounds differ from previous proteasome inhibitors by exhibiting uncompetitive reversible inhibition rather than competitive inhibition. This technology is effective against bortezomib-resistant Multiple Myeloma cells and has potential as a novel asthma treatment. Key BenefitsEffective against drug-resistant myeloma cellsHas potential to target other cancers and diseasesNovel mechanism of inhibitionSimple chemical synthesis ApplicationsTreating Multiple MyelomaInhibit proteasome function to kill cancer cellEffective against bortezomib-resistant strainsTreating asthmaSame inhibition pathway Patent Status: Under review Licensing Rights Available Full licensing rights available Inventors: Aaron Odom, Jetze Tepe, Teri Lansdall Tech ID: TEC2016-0123 Alternative contact due to temporary leave: Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.
- *Abstract
-
None
- *Principal Investigator
-
Name: Aaron Odom, Professor
Department: Department of Chemistry
Name: Jetze Tepe, Associate Professor
Department: Department of Chemistry
Name: Theresa Lansdall, Research Assistant
Department: Department of Chemistry
- Country/Region
- USA
For more information, please click Here
